Shotgun Partnering Approach for Vertex in All-Oral HCV Race
Moving aggressively to gain ground in the race for an all-oral hepatitis C virus (HCV) regimen, Vertex Pharmaceuticals Inc., of Cambridge, Mass., has put forward its nucleotide analogue HCV polymerase inhibitor, VX-135, in two collaborative, proof-of-concept Phase II trials with two different pharma partners.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter